NovoCure Reports Q3 2026 Financial Results

NovoCure reported Q3 2026 revenue of $193.4 million, up 15.7% from $167.2 million a year earlier, and a net loss of $10.44 million, or $0.09 per share. The loss narrowed from $37.27 million, or $0.33 per share, in Q3 2025. Results beat FactSet estimates of a $0.23-per-share loss and $182.3 million in revenue.